{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:03:57Z","timestamp":1747109037091,"version":"3.40.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,12]]},"DOI":"10.7759\/cureus.83956","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:22:23Z","timestamp":1747059743000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Direct Oral Anticoagulants (DOACs) in Cancer-Associated Thrombosis: A Comprehensive Review of the Literature"],"prefix":"10.7759","author":[{"given":"Muzammil  R","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Barsoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyal","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sese Ekolle Mbonde","family":"Mudika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraja","family":"Reghu Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanzeela F","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya H","family":"Dahleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Ambreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamanda","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muteeba","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00029-3","article-title":"Proper application of anticoagulation therapy on cancer-associated venous thrombosis","volume":"59","author":"Yhim HY","year":"2024","unstructured":"Yhim HY. Proper application of anticoagulation therapy on cancer-associated venous thrombosis. Blood Res. 2024, 59:25. 10.1007\/s44313-024-00029-3","journal-title":"Blood Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2025.109259","article-title":"Unveiling the trends: growing cancer and venous thromboembolism mortality in older adults in the United States, 1999-2020","volume":"247","author":"Saad M","year":"2025","unstructured":"Saad M, Batool RM, Waqas SA, et al.. Unveiling the trends: growing cancer and venous thromboembolism mortality in older adults in the United States, 1999-2020. Thromb Res. 2025, 247:109259. 10.1016\/j.thromres.2025.109259","journal-title":"Thromb Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Razak NB","year":"2018","unstructured":"Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018, 10:380. 10.3390\/cancers10100380","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07323.x","article-title":"Virchow and his triad: a question of attribution","volume":"143","author":"Bagot CN","year":"2008","unstructured":"Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008, 143:180-90. 10.1111\/j.1365-2141.2008.07323.x","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan E","year":"2017","unstructured":"Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017, 22:199-207. 10.1634\/theoncologist.2016-0214","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-021-00319-1","article-title":"Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis","volume":"19","author":"Wumaier K","year":"2021","unstructured":"Wumaier K, Li W, Chen N, Cui J. Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thromb J. 2021, 19:68. 10.1186\/s12959-021-00319-1","journal-title":"Thromb J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso M","year":"2021","unstructured":"Verso M, Munoz A, Bauersachs R, et al.. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021, 148:371-81. 10.1016\/j.ejca.2021.02.026","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.01.021","article-title":"The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study","volume":"235","author":"Sueta D","year":"2024","unstructured":"Sueta D, Yamashita Y, Morimoto T, et al.. The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study. Thromb Res. 2024, 235:107-15. 10.1016\/j.thromres.2024.01.021","journal-title":"Thromb Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob GE","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, et al.. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018, 378:615-24. 10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller CS","year":"2012","unstructured":"Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012, 110:453-60. 10.1016\/j.amjcard.2012.03.049","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.907197","article-title":"Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis","volume":"9","author":"Zeng S","year":"2022","unstructured":"Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:907197. 10.3389\/fcvm.2022.907197","journal-title":"Front Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.1.96","article-title":"Warfarin-induced skin necrosis","volume":"26","author":"Kakagia DD","year":"2014","unstructured":"Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. Ann Dermatol. 2014, 26:96-8. 10.5021\/ad.2014.26.1.96","journal-title":"Ann Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1345622","article-title":"Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease","volume":"10","author":"Kampouraki E","year":"2017","unstructured":"Kampouraki E, Kamali F. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease. Expert Rev Clin Pharmacol. 2017, 10:789-97. 10.1080\/17512433.2017.1345622","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.04.015","article-title":"Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial","volume":"226","author":"Potere N","year":"2023","unstructured":"Potere N, Di Nisio M, Porreca E, et al.. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial. Thromb Res. 2023, 226:82-5. 10.1016\/j.thromres.2023.04.015","journal-title":"Thromb Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-4661-3","article-title":"Duration of anticoagulant therapy and VTE recurrence in patients with cancer","volume":"27","author":"Khorana AA","year":"2019","unstructured":"Khorana AA, McCrae KR, Milentijevic D, et al.. Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Support Care Cancer. 2019, 27:3833-40. 10.1007\/s00520-019-4661-3","journal-title":"Support Care Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli G","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, et al.. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020, 382:1599-607. 10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young AM","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, et al.. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018, 36:2017-23. 10.1200\/JCO.2018.78.8034","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12559","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active cancer","volume":"35","author":"Ogata M","year":"2021","unstructured":"Ogata M, Ama Y, Ogata T, Hirabatake M, Yasui H, Satake H. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active cancer. In Vivo. 2021, 35:2747-53. 10.21873\/invivo.12559","journal-title":"In Vivo"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13584","article-title":"Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats","volume":"26","author":"O'Connell C","year":"2021","unstructured":"O'Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist. 2021, 26:e8-e16. 10.1002\/onco.13584","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar PL","year":"2022","unstructured":"Mar PL, Gopinathannair R, Gengler BE, et al.. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol. 2022, 15:e007956. 10.1161\/CIRCEP.121.007956","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder FI","year":"2020","unstructured":"Mulder FI, Bosch FT, Young AM, et al.. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020, 136:1433-41. 10.1182\/blood.2020005819","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller HR","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, Grosso MA, et al.. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013, 369:1406-15. 10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman S","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al.. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009, 361:2342-52. 10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli G","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al.. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013, 369:799-808. 10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz J","year":"2017","unstructured":"Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017, 10:135-43. 10.2147\/IJNRD.S105771","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref26","article-title":"Apixaban","author":"Agrawal A","year":"2025","unstructured":"Agrawal A, Kerndt CC, Manna B. Apixaban. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck W","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014, 53:1-16. 10.1007\/s40262-013-0100-7","journal-title":"Clin Pharmacokinet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key NS","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, et al.. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020, 38:496-520. 10.1200\/JCO.19.01461","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010301","article-title":"Choice and duration of anticoagulation for venous thromboembolism","volume":"13","author":"Malik A","year":"2024","unstructured":"Malik A, Ha NB, Barnes GD. Choice and duration of anticoagulation for venous thromboembolism. J Clin Med. 2024, 13:301. 10.3390\/jcm13010301","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier M","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al.. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019, 380:711-9. 10.1056\/NEJMoa1814468","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli G","year":"2018","unstructured":"Agnelli G, Becattini C, Bauersachs R, et al.. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost. 2018, 118:1668-78. 10.1055\/s-0038-1668523","journal-title":"Thromb Haemost"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.05.014","article-title":"Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial","volume":"216","author":"Brandt W","year":"2022","unstructured":"Brandt W, Brown C, Wang TF, et al.. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thromb Res. 2022, 216:8-10. 10.1016\/j.thromres.2022.05.014","journal-title":"Thromb Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389516","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh S","year":"2023","unstructured":"Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared decision making in the care of patients with cancer. Am Soc Clin Oncol Educ Book. 2023, 43:e389516. 10.1200\/EDBK_389516","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga A","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al.. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023, 34:452-67. 10.1016\/j.annonc.2022.12.014","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder FI","year":"2019","unstructured":"Mulder FI, Candeloro M, Kamphuisen PW, et al.. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019, 104:1277-87. 10.3324\/haematol.2018.209114","journal-title":"Haematologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients\u00a0with cancer: JACC review topic of the week","volume":"73","author":"Mosarla RC","year":"2019","unstructured":"Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients\u00a0with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019, 73:1336-49. 10.1016\/j.jacc.2019.01.017","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2023.11.005","article-title":"Care pathways for patients with cancer-associated thrombosis: from diagnosis to long-term follow-up","volume":"117","author":"Sevestre MA","year":"2024","unstructured":"Sevestre MA, Gaboreau Y, Douriez E, et al.. Care pathways for patients with cancer-associated thrombosis: from diagnosis to long-term follow-up. Arch Cardiovasc Dis. 2024, 117:6-15. 10.1016\/j.acvd.2023.11.005","journal-title":"Arch Cardiovasc Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi JJ","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016, 375:1457-67. 10.1056\/NEJMra1100265","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/361682-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-associated-thrombosis-a-comprehensive-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:22:23Z","timestamp":1747059743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/361682-the-role-of-direct-oral-anticoagulants-doacs-in-cancer-associated-thrombosis-a-comprehensive-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.83956","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}